HuagongsheHuagongshe Chemistry Print Report · For research reference only
Pravastatin Diol Lactone Di-(tert-butyldimethylsilyl) Ether → (4R,6R)-6-([1S,2S,6S,8S,8aR]-2-{1,2,6,7,8,8a-Hexahydro-6-t-butyldimethylsilyloxy-8-[(2RS)-2-(2-methylphenoxy)-2-methylvaleryloxy]-2-methyl-1-naphthyl}ethyl)tetrahydro-4-t-butyldimethylsilyloxy-2H-pyran-2-one
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | Pravastatin Diol Lactone Di-(tert-butyldimethylsilyl) Ether | HCID 14600906 | — |
| Reactant | (2RS)-2-(2-methylphenoxy)-2-methylvaleric acid | HCID 18988407 | — |
| Product | (4R,6R)-6-([1S,2S,6S,8S,8aR]-2-{1,2,6,7,8,8a-Hexahydro-6-t-butyldimethylsilyloxy-8-[(2RS)-2-(2-methylphenoxy)-2-methylvaleryloxy]-2-methyl-1-naphthyl}ethyl)tetrahydro-4-t-butyldimethylsilyloxy-2H-pyran-2-one | HCID 56977077 | 57.1% |
Reaction Steps
A procedure similar to that described in Example 10, above, was followed, but using 0.35 g of (2RS)-2-(2-methylphenoxy)-2-methylvaleric acid and 0.46 g of (4R,6R)-6-{(1S,2S,6S,8S,8aR)-2-[1,2,6,7,8,8a-hexahydro-6-t-butyldimethylsilyloxy-8-hydroxy-2-methyl-1-naphthyl]ethyl}tetrahydro-4-t-butyldimethylsilyloxy-2H-pyran-2-one [prepared as described in Example B, above], to give 0.36 g of the title compound as a colorless foam.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US05491167 |
| Source dataset | uspto-grants-1996_02 |
| ORD ID | ord-59363167bf8c43d4b2f0f1ab90217a87 |
| Source note | uspto-grants-1996_02 |